Tivicay (dolutegravir) will be
listed on the Pharmaceutical
Benefits Scheme (PBS) as of 01 Apr.
Tivicay is an integrase inhibitor
which blocks the HIV virus from
spreading through the immune
system, manufacturer ViiV
Healthcare said.
St Vincent’s Hospital Immunology
and Infectious Diseases Unit
director of HIV Professor Andrew
Carr said the listing was an
important development in the
treatment of HIV.The above article was sent to subscribers in Pharmacy Daily's issue from 28 Mar 14 To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 28 Mar 14
MONTU Group, its subsidiary Alternaleaf Pty Ltd, and their common director Christopher Strauch are facing legal action by the Therapeutic Goods Administration (TGA) in the Federal Court of Australia for alleged unlawful advertising on the effectiveness of their medicinal cannabis products.
FREE Pharmacy Daily subscription - never miss another story!
to top
Subscribe to Pharmacy Daily
Pharmacy Daily subscription confirmation
Thank you for signing up! Check your email inbox – you should shortly receive a message with a link which must be clicked to confirm your subscription.
Once you’ve done that you will begin receiving Pharmacy Daily as soon as the next issue is published.